Condition: Breast Cancer Surgery · Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Patients with a germline pathogenic variant (GPV) in high-penetrance breast cancer susceptibility genes who are considering risk reducing mastectomy (RRM) often strongly desire to keep their nipple areola complex but inquire as to whether it is safe to do so. Relative to traditional or skin sparing mastectomy (SSM) techniques, nipple sparing mastectomy (NSM) is associated with improved psychosocial and sexual well-being and is significantly better for body image and reducing feelings of disfigurement. Despite this, guidelines have yet to endorse the use of NSM over other RRM techniques, stating that more data and longer follow-up are needed to confirm it as a safe and effective strategy in GPV carriers. As NSM was not routinely adopted in high-risk patient populations undergoing RRM before 2010, there has been little data to inform the long-term oncologic safety of NSM. Well-designed studies have reported low to negligible rates of subsequent breast cancer in BRCA1/2 carriers following NSM, but have been limited by short median follow-up of less than 3 years. The current study is designed to confirm, with longer follow-up, prior findings on the oncologic safety of NSM in unaffected BRCA1/2 carriers. The investigators will also expand data to other high-penetrance GPV carriers, including PALB2, CDH1, PTEN, and TP53, for whom there is little-to-no data on outcomes following RRM.
This description comes directly from the study's public registry record.
Stephanie Wong, MD · 5143408222 · sm.wong@mcgill.ca
Sarah Sabboobeh, MSc · 5143408222 · sarah.sabboobe@ladydavis.ca
Always discuss trial participation with your own doctor first.
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Brigham and Women's Hospital - Dana-Farber Brigham Cancer Center | Boston, Massachusetts, United States | Not Yet Recruiting |
| Memorial Sloan Kettering Cancer Center (MSKCC) | New York, New York, United States | Not Yet Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Melbourne, Peter MacCallum Cancer Center | Melbourne, Australia | Not Yet Recruiting |
| Ziekenhuis Aan de Stroom | Antwerp, Belgium | Active Not Recruiting |
| University of Calgary | Calgary, Alberta, Canada | Recruiting |
| Hamilton Health Sciences | Hamilton, Ontario, Canada | Recruiting |
| Women's College Hospital, University of Toronto | Toronto, Ontario, Canada | Not Yet Recruiting |
| Jewish General Hospital | Montreal, Quebec, Canada | Recruiting |
| CHU de Quebec Université laval | Québec, Quebec, Canada | Recruiting |
| Champalimaud Foundation, University of Lisbon | Lisbon, Portugal | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06888388